These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 16775667

  • 1. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective.
    Szucs TD, Holm MV, Schwenkglenks M, Zhang Z, Weintraub WS, Burnier M, Erne P.
    Cardiovasc Drugs Ther; 2006 Jun; 20(3):193-204. PubMed ID: 16775667
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
    Weintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, Ishak J, Goldberg R, Tooley J, Willke R, Pitt B.
    Circulation; 2005 Mar 08; 111(9):1106-13. PubMed ID: 15723981
    [Abstract] [Full Text] [Related]

  • 3. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z, Mahoney EM, Kolm P, Spertus J, Caro J, Willke R, Weintraub WS.
    Am J Cardiovasc Drugs; 2010 Mar 08; 10(1):55-63. PubMed ID: 20104935
    [Abstract] [Full Text] [Related]

  • 4. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C, Burch J, Suekarran S, Walker S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Lorgelly P, Fenwick L, Palmer S.
    Health Technol Assess; 2010 May 08; 14(24):1-162. PubMed ID: 20492762
    [Abstract] [Full Text] [Related]

  • 5. Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
    Croom KF, Plosker GL.
    Pharmacoeconomics; 2005 May 08; 23(10):1057-72. PubMed ID: 16235978
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
    de Pouvourville G, Solesse A, Beillat M.
    Arch Cardiovasc Dis; 2008 Sep 08; 101(9):515-21. PubMed ID: 19041835
    [Abstract] [Full Text] [Related]

  • 7. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH, Abuissa H, Pitt B.
    Diabetes Obes Metab; 2008 Jun 08; 10(6):492-7. PubMed ID: 17490427
    [Abstract] [Full Text] [Related]

  • 8. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
    Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J, EPHESUS Investigators.
    J Am Coll Cardiol; 2005 Aug 02; 46(3):425-31. PubMed ID: 16053953
    [Abstract] [Full Text] [Related]

  • 9. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
    Gheorghiade M, Khan S, Blair JE, Harinstein ME, Krum H, Mukherjee R, Pitt B, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival (EPHESUS) Investigators.
    Am Heart J; 2009 Sep 02; 158(3):437-43. PubMed ID: 19699868
    [Abstract] [Full Text] [Related]

  • 10. Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS).
    Chan PS, Soto G, Jones PG, Nallamothu BK, Zhang Z, Weintraub WS, Spertus JA.
    Circulation; 2009 Jan 27; 119(3):398-407. PubMed ID: 19139382
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of eplerenone plus standard treatment compared with standard treatment in patients with myocardial infarction complicated by left ventricular systolic dysfunction and heart failure in the Netherlands.
    van Genugten ML, Weintraub WS, Zhang Z, Voors AA.
    Neth Heart J; 2005 Nov 27; 13(11):393-400. PubMed ID: 25696430
    [Abstract] [Full Text] [Related]

  • 12. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM, Vincent J, Pitt B, Zannad F.
    Circulation; 2009 May 12; 119(18):2471-9. PubMed ID: 19398668
    [Abstract] [Full Text] [Related]

  • 13. Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial.
    Iqbal J, Fay R, Adlam D, Squire I, Parviz Y, Gunn J, Pitt B, Zannad F.
    Eur J Heart Fail; 2014 Jun 12; 16(6):685-91. PubMed ID: 24706498
    [Abstract] [Full Text] [Related]

  • 14. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators.
    N Engl J Med; 2003 Apr 03; 348(14):1309-21. PubMed ID: 12668699
    [Abstract] [Full Text] [Related]

  • 15. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.
    Adamopoulos C, Ahmed A, Fay R, Angioi M, Filippatos G, Vincent J, Pitt B, Zannad F, EPHESUS Investigators.
    Eur J Heart Fail; 2009 Nov 03; 11(11):1099-105. PubMed ID: 19875410
    [Abstract] [Full Text] [Related]

  • 16. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, EPHESUS Investigators.
    Circulation; 2008 Oct 14; 118(16):1643-50. PubMed ID: 18824643
    [Abstract] [Full Text] [Related]

  • 17. Cost effectiveness of eplerenone in patients with chronic heart failure.
    Ademi Z, Pasupathi K, Krum H, Liew D.
    Am J Cardiovasc Drugs; 2014 Jun 14; 14(3):209-16. PubMed ID: 24610254
    [Abstract] [Full Text] [Related]

  • 18. Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Olivier A, Girerd N, Michel JB, Ketelslegers JM, Fay R, Vincent J, Bramlage P, Pitt B, Zannad F, Rossignol P, EPHESUS Investigators.
    Int J Cardiol; 2017 Aug 15; 241():344-350. PubMed ID: 28284500
    [Abstract] [Full Text] [Related]

  • 19. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr 15; 15(82):46-9. PubMed ID: 16604728
    [Abstract] [Full Text] [Related]

  • 20. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
    Carillo S, Zhang Y, Fay R, Angioi M, Vincent J, Sutradhor SC, Ahmed A, Pitt B, Zannad F.
    Arch Cardiovasc Dis; 2014 Mar 15; 107(3):149-57. PubMed ID: 24630753
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.